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Abstract
In 2012, the Netherlands Association of Cardiothoracic Surgery accepted the new guidelines of the European Association for Cardio-
Thoracic Surgery on antiplatelet and anticoagulation management in cardiac surgery. The aim of our study was to evaluate knowledge and
implementation of these guidelines in Dutch cardiothoracic centres 8 months later, speciﬁcally after biological aortic valve replacement.
One month prior to and 8 months after acceptance of the new guidelines, a questionnaire was sent to all 16 Dutch cardiothoracic centres
about their current anticoagulation management after biological aortic valve replacement, their knowledge and implementation of the
guidelines. All centres returned the questionnaire. Fifteen centres declared knowledge of the guidelines of which two adjusted their antic-
oagulation therapy. Four declared they did not follow the guidelines. However, of the remaining 11 centres, only 7 followed the guidelines.
Between the centres, current anticoagulation therapy varied from aspirin to coumarin with different dosages and durations. Despite ac-
ceptance of the guidelines, only 7 of 16 centres followed them, and there remains great variability in the postoperative anticoagulation
management after biological aortic valve replacement in Netherlands.
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INTRODUCTION
The necessity for postoperative anticoagulation (AC) in patients
after bioprosthetic aortic valve replacement (bAVR) has been
studied repeatedly over the past years; however, there continues
to be a lack of evidence. It is suspected that, in the ﬁrst 3 months
after biological valve replacement, there is a higher risk of
thromboembolic events, due to the underlying cause of the valve
disease, the design of the valve (stented or stentless) and the time
needed for endothelialization of the suture-ring and the sutures of
the new valve prosthesis [1, 2].
However, current available investigations do not show the su-
periority of vitamin K antagonists. They even suggest that treat-
ment with antiplatelet therapy alone in the early postoperative
period is adequate, although most of the studies are retrospective,
they do not have enough power to show signiﬁcance and follow-
up is inconsistent [2, 3].
Also, recent guidelines are not consistent: All (recently) changed
their advice to a regimen of aspirin alone, in the absence of
thromboembolic risk factors such as atrial ﬁbrillation, enlarged left
atrium or left ventricle or thrombus, although they mention a
vitamin K antagonist as a reasonable alternative, and some direct
one to other guidelines [1, 4–11].
In May 2012, during their biannual meeting, the Netherlands
Association for Cardiothoracic Surgery (NVT) conﬁrmed the
guidelines of the European Association for Cardio-Thoracic
Surgery (EACTS) on antiplatelet and anticoagulation management
in cardiac surgery (EACTS-AC guidelines), with the intention to im-
plement these guidelines in daily practice and to create uniformity
of management [11].
The aim of this study was to evaluate knowledge and im-
plementation of these EACTS-AC guidelines in Dutch cardiothoracic
centres after conﬁrmation in May 2012, particularly the recommen-
dation on AC after tissue aortic valve replacement stating: ‘After
tissue aortic valve replacement and in the absence of other indica-
tions for anticoagulation, antiplatelet therapy alone is adequate’
[11]. Furthermore, we wondered if these guidelines resulted in more
uniform management and therefore checked on dosage, target
international normalized ratio (INR) and duration of AC therapy.
METHODS
In April 2012, 1 month prior acceptance of the EACTS-AC guide-
lines, a survey to evaluate current AC management after bAVR was
administered in all 16 cardiothoracic centres in Netherlands to
one cardiac surgeon (or the oldest in training) in each centre
about general AC management after bAVR in their centre (Table 1,
question 1a, 4). The same questionnaire, completed with
†Presented at the biannual meeting of the Netherlands Association for
Cardiothoracic Surgery, 31 May 2013.
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additional questions about dosage, duration of therapy and
knowledge and implementation of the guidelines was sent eight
months ( January 2013) after the acceptance of the EACTS-AC
guidelines by the NVT (May 2012) to the same cardiac surgeon (or
the oldest in training) in each centre (Table 1, question 1b, 2, 3).
RESULTS
All cardiothoracic centres participated voluntarily and completed
the survey in 2012 and 2013. Results are given in Table 2.
In 2012, prior to acceptance of the guidelines, four centres
(25%) (Centres 1–4) prescribed only aspirin and four centres (25%)
(Centres 10–12, 14) started with coumarin and switched to aspirin
after 6 weeks or 3 months of coumarin use. Three centres
(18.75%) (Centres 5–7) based their decision on risk factors of the
patient, which they identiﬁed by using the CHAD2 score or the
risk factors described in the EACTS-AC guidelines [11, 12]. Two
centres (12.5%) (Centres 8 and 9) prescribed aspirin or coumarin
depending on the type of valve implanted-stented or stentless,
and two centres (12.5%) (Centres 15 and 16) prescribed a combin-
ation of coumarin and aspirin. One centre (6.25%) (Centre 13) did
not prescribe any further treatment after 3 months of coumarin.
In 2013, after acceptance of the guidelines, six centres (37.5%)
(Centres 1–6) prescribed only aspirin and one (6.25%) (Centre 7)
prescribed aspirin or coumarin depending on risk factors.
Five centres (31.25%) (Centres 10–14) prescribed coumarin of
which one switched therapy after 3 months. Two centres (12.5%)
(Centres 15 and 16) prescribed a double therapy with coumarin
and aspirin and stopped coumarin after 3 months. Two centres
(12.5%) (Centres 8 and 9) prescribed coumarin or aspirin depend-
ing on the type of valve implanted-stented or stentless.
This leads to six centres that always prescribe aspirin, four
centres that prescribe aspirin or coumarin depending on valve
type or risk factors, two centres that always prescribe a combin-
ation of aspirin and coumarin and four centres that always pre-
scribe coumarin.
Of the 12 centres prescribing aspirin, the duration of therapy
was 3 months in one centre (Centre 7), lifelong in 10 centres
(Centres 1–6, 15, 16) and lifelong but starting after 3 months in
one centre (Centre 11).
Five centres (Centres 1, 3, 5, 11, and 15) prescribed 80 mg of
acetyl salicylic acid (ASA) and ﬁve centres (Centres 2, 6, 7, 8, and
16) prescribed 100 mg of carbasalate calcium. The dosage was
unknown for two centres (Centres 4 and 9).
Of the 10 centres prescribing coumarin, one (Centre 9)
prescribed Fenprocoumon, and the other 9 (Centres 7, 8, 10–16)
prescribed Acenocoumarol. The duration of therapy was 6 weeks
in two centres (Centres 9 and 12), 3 months in seven centres
(Centres 8, 10, 11, 13–16) and lifelong in one centre (Centre 7),
but only in the presence of risk factors according to the EACTS-AC
guidelines. Target INR ranged between 2 and 2.5 in two centres
(Centres 7 and 8), 2–3 in four centres (Centres 10 and 14–16), 2 .5–
3 in one centre (Centre 12) and 2. 5–3. 5 in two centres (Centres
11 and 13). The target INR was unknown for one centre (Centre 9).
Thus, the duration of therapy varied from 3 months to lifelong
for aspirin, and 6 weeks to 3 months for coumarin, with different
dosages, although most centres indicated that the ﬁnal decision on
the duration of treatment is made by the patient’s own cardiologist.
On the second question, 15 centres declared knowing the
EACTS-AC guidelines. Only one centre (Centre 11) declared not
knowing them, and consequently did not know if these guidelines
had been followed. Of the other 15 centres, 11 claimed to have
followed and 4 not to have followed the guidelines.
DISCUSSION
Despite the acceptance of the EACTS-AC guidelines by the
members of the NVT in May 2012, there is one centre that
claimed not to know these guidelines and consequently did not
follow them nor changed management.
Of the 15 centres that did know the guidelines, 4 centres
declared not following them, which is possible by law, although
deviation needs explanation, especially when it is structural. We
do not know the arguments of these four centres, nor do we know
if deviation from the guidelines in other centres is mentioned and
explained in institution protocols, because this was not an item in
our questionnaire.
Two centres changed their management according to these
guidelines. Together with the four centres that had already pre-
scribed aspirin only, and the one centre prescribing aspirin
Table 1: Questionnaire regarding AC management after bAVR
Question Answer (Mark the applicable)
1a Which type of anticoagulation therapy do you start after biological
aortic valve replacement?
1b Which type of anticoagulation therapy do you start after biological
aortic valve replacement?
• None
• Aspirin; dosage: duration of therapy:
• Vitamin K antagonist; target INR: duration of therapy:
• Combination therapy; dosage: target INR: duration of therapy:
• NOAC; dosage: duration of therapy:
• Other, nl:
2 Are you aware of a guideline about anticoagulation management? • Yes
• No
3 Do you follow these guidelines ? • Yes
• No
4 Cardiothoracic centre I work in
bAVR: bioprosthetic aortic valve replacement; NOAC: new anticoagulants; INR: international normalized ratio.
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depending on risk factors, this leads to seven centres following
and eight centres deviating from the guidelines in 2013. These
eight centres did not prescribe aspirin according to the guidelines,
but they prescribed coumarin as an acceptable alternative, as men-
tioned in the same guidelines, mainly because of the absence of
clear evidence in favour of aspirin only. In view of these ﬁndings,
we can conclude that, with an audit, it is not enough to just ask if a
centre follows the guidelines, but that this should be reﬂected in
daily practice as well.
Dosage, target INR and duration of therapy differ between
centres, and since no speciﬁc dosage or duration is recommended
in the guidelines, it will be difﬁcult to reach uniformity. This
means that despite implementation of guidelines, a uniform man-
agement has not been reached.
Remarkably, ﬁve centres prescribe 80 mg of ASA, whereas ﬁve
other centres prescribe 100 mg of carbasalate calcium, which is
equivalent in action but double in price [13]. Interestingly, new
anticoagulants (NOACs) such as Apixaban (Eliquis, Bristol-Myers
Squibb, Anagni, Italy), Rivaroxaban (Bayer, Leverkusen, Germany)
and Dabigatran (Boehringer Ingelheim, Ingelheim am Rhein,
Germany) were currently not prescribed by any centre, although
only Dabigatran has a registered contraindication to its use with
valve prostheses [13].
These ﬁndings may seem unexpected and confusing, but they
are in line with earlier, comparable studies, mainly in the UK [4, 14–
16]. In the Action Registry in 2008, Colli showed that 33% of centres
prescribed aspirin according to the guidelines, 43% of centres pre-
scribed a vitamin K antagonist, 20% prescribed both and 4% did
not prescribe anything from discharge until Month 3 [4]. In 2010,
194 cardiac surgeons in the UK were surveyed by Nowell.
Eighty-eight percent responded, of which 58% followed the guide-
lines by prescribing aspirin for 3 months (10%) or more (48%), 15%
prescribed warfarin for 3 months, 10% prescribed no medication at
all and 17% followed other regimens [15]. In 2011, a national audit
in the UK among 37 hospitals showed that 62.2% of them were
aware of the current EACTS-AC guidelines; 11.6% followed these
guidelines, 73.1% did not and 15.3% did not know of them [15].
The variability in prescription in our study of the centres in
Netherlands is not different from that in these surveys with 44%
prescribing aspirin, 31% prescribing coumarin, 13% prescribing
both and 12% following other regimens, although awareness of
the guidelines is higher (94%).
LIMITATIONS
Although all centres participated in this survey, there is the possi-
bility of variation in AC management between surgeons in the
same centre. Another important limitation of this study is that
cardiac surgeons start AC management directly postoperatively,
but when patients return to their attending cardiologists, they will
take a decision about the ﬁnal type and duration of therapy. These
cardiologists did not participate in this survey, so we have no
documented data of AC therapy after discharge.
Furthermore, adherence to the guidelines is not obligatory;
they serve as a guide in best practice for professionals and as a
standard of care for patients and their lawyers, although deviation
from them needs argumentation, especially when this is structural
[17]. We did not ask centres for their motivation in deviating from
the guidelines, nor if this deviation is mentioned and explained in
institution protocols.
CONCLUSION
Eight months after acceptance of the EACTS guidelines on antipla-
telet and AC therapy, little has changed in AC management after
bAVR in the direct postoperative care in cardiothoracic centres
in Netherlands. Despite the fact that 15 of 16 centres declared
knowing the guidelines, only 7 centres did follow them.
Furthermore, the implementation of this guideline did not result
in a uniform AC management. Research and publication may lead
to more centres following these guidelines.
Table 2: AC therapy in the Netherlands 2012 and 2013
2012 Prior to the acceptance of the EACTS guidelines 2013 After the acceptance of the EACTS guidelines
Centre Type of AC therapy K Type of AC therapy S FG
1 Aspirin X Aspirin X X
2 Aspirin X Aspirin X X
3 Aspirin X Aspirin X X
4 Aspirin X Aspirin X X
5 Aspirin, Coumarin in high-risk patients (CHAD) X Aspirin X X
6 Aspirin <70 years, LMWH>70 years, Coumarin in high-risk
patients (EACTS guideline)
X Aspirin X X
7 Aspirin, Coumarin in high-risk patients (EACTS guideline) X Aspirin or Coumarin depending on risk X X
8 Aspirin if stentless valve, Coumarin if stented valve X Aspirin if stentless valve, Coumarin if stented valve X
9 Aspirin if stentless valve, Coumarin if stented valve X Aspirin if stentless valve, Coumarin if stented valve
10 Coumarin for 3 months, then switch to Aspirin X Coumarin
11 Coumarin for 3 months, then switch to Aspirin Coumarin
12 Coumarin for 6 weeks, then switch to Aspirin X Coumarin
13 Coumarin X Coumarin X
14 Coumarin for 3 months, then switch to Aspirin X Coumarin X
15 Coumarin and Aspirin for 3 months X Coumarin and Aspirin, stop Coumarin after 3 months
16 Coumarin for 3 months and Aspirin lifelong X Coumarin and Aspirin, stop Coumarin after 3 months X
K: knowledge of the guidelines; S: supposition to follow the guidelines, FG: follow the guidelines; LMWH: low-molecular-weight heparin; AC: anticoagulation.
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